NCT06154187
Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
Pharmbio Korea Co., Ltd.·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Osteoporosis
- Drug/Device/Intervention
- PBK_L2201
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Pharmbio Korea Co., Ltd.
- Location
- Seoul, South Korea
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Feb 01, 2024
- End date
- Nov 01, 2025
- Enrollment
- 60 participants
Primary outcome
Bone mineral density (BMD) change rate
Summary
This clinical trial was multicenter, randomized, double-blind, placebo-controlled, parallel,
 phase III bridge study.
ICD-10 classifications
Osteoporosis, unspecifiedOther osteoporosisIdiopathic osteoporosisOsteoporosis in diseases classified elsewherePostmenopausal osteoporosis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06154187
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06154187 through Pure Global AI's free database. This Phase 3 trial is sponsored by Pharmbio Korea Co., Ltd. and is currently Not yet recruiting. The study focuses on Osteoporosis. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.